In 2025, WuXi AppTec, China’s leading pharmaceutical R&D services company, is projected to achieve revenue of RMB 45.456 billion. This figure not only underscores the company’s sustained leadership in the global life sciences and contract research organization (CXO) sector but also reflects the successful implementation of its ‘integrated, end-to-end’ drug discovery and development platform strategy. In recent years, WuXi AppTec has effectively navigated geopolitical uncertainties and industry cyclicality through global expansion, technological platform enhancements, and deeper client collaborations. The targeted revenue of RMB 45.456 billion represents significant growth compared to its actual 2023 performance, highlighting strong market confidence in its service capabilities. Despite a complex international landscape, this outlook demonstrates the resilience and growth potential of Chinese CXO companies. Looking ahead, WuXi AppTec will continue to focus on supporting innovative drug development and expanding into cutting-edge areas such as cell and gene therapy and AI-driven drug discovery, delivering more efficient and cost-effective R&D solutions to global clients.
2025年，中国领先的医药研发服务公司药明康德预计实现营业收入454.56亿元人民币。这一数据不仅体现了公司在全球生命科学和医药研发外包（CXO）领域的持续领先地位，也反映出其‘一体化、端到端’新药研发服务平台战略的成功落地。近年来，药明康德通过全球化布局、技术平台升级以及客户合作深化，有效应对了地缘政治波动与行业周期性调整带来的挑战。454.56亿元的营收目标，较2023年实际收入有显著增长，彰显了市场对其服务能力的高度认可。同时，该业绩预期也表明，尽管国际环境复杂多变，中国CXO企业仍具备强大的韧性和增长潜力。未来，药明康德将继续聚焦创新药研发支持，拓展细胞与基因治疗、AI驱动药物发现等前沿领域，为全球客户提供更高效、更具成本效益的研发解决方案。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/13024.html